GlassScriptPhysician profile
Gary D Peterson
NPI 1629147731
$7,337.73
in general payments reported to CMS, 2019-2025
27 companies · $897 in 2025
The $897 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,821 · 2022: $1,847 · 2023: $1,357 · 2024: $1,415 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,557.50 | 2022-2025 | |
| Abbvie INC. | $785.60 | 2021-2025 | |
| Galderma Laboratories, L.P. | $771.86 | 2021-2025 | Aklief, Oracea, Twyneo |
| Epi Health, LLC | $640.17 | 2021-2022 | |
| Dermavant Sciences, INC. | $591.75 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $505.61 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $360.69 | 2021-2025 | Ilumya |
| Pfizer INC. | $309.99 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $232.57 | 2021 | |
| Janssen Biotech, INC. | $224.62 | 2021-2025 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $206.55 | 2022-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $204.48 | 2021-2025 | Dupixent, Libtayo |
| Merz North America, INC. | $196.04 | 2022-2025 | Xeomin |
| Incyte Corporation | $183.65 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $107.32 | 2021-2024 | Jublia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $94.47 | 2023-2024 | Otezla |
| Janssen Scientific Affairs, LLC | $72.05 | 2021 | |
| Krystal Biotech INC | $53.77 | 2023-2025 | Vyjuvek |
| Lilly USA, LLC | $53.65 | 2023-2024 | Taltz, Olumiant, Zepbound |
| Organon LLC | $36.80 | 2025 | Vtama |
| Biocon Biologics INC | $27.23 | 2024 | Hulio |
| Dermira, INC. | $24.45 | 2021 | |
| Convatec INC. | $23.96 | 2025 | |
| Ucb, INC. | $20.47 | 2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $18.95 | 2024 | Zoryve |
| Sandoz INC. | $18.27 | 2025 | Hyrimoz |
| Revance Therapeutics, INC. | $15.26 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.